Comparative Pharmacology
Head-to-head clinical analysis: DIVALPROEX SODIUM versus XCOPRI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIVALPROEX SODIUM versus XCOPRI.
DIVALPROEX SODIUM vs XCOPRI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases brain concentrations of gamma-aminobutyric acid (GABA), blocks voltage-gated sodium channels, and modulates T-type calcium channels.
XCOPRI (cenobamate) is a tetrazole derivative anticonvulsant that reduces neuronal excitability through inhibition of voltage-gated sodium channels (persistent sodium current) and positive allosteric modulation of GABA-A receptors.
10-15 mg/kg/day orally in divided doses; increase by 5-10 mg/kg/week; maximum 60 mg/kg/day. Extended-release: 25 mg/kg/day orally; increase by 15 mg/kg/day at weekly intervals; maximum 60 mg/kg/day.
Oral, 100 mg once daily for 2 weeks, then increase to 200 mg once daily. Maximum dose 400 mg once daily.
None Documented
None Documented
9-16 hours (terminal); shorter in children (6-9 hours) and longer in hepatic disease or elderly; clinical context: twice-daily dosing provides stable trough concentrations.
50-70 hours, allowing once-daily dosing. Steady-state is reached in approximately 2 weeks.
Renal: <3% unchanged; primarily hepatic metabolism (glucuronidation, beta-oxidation, cytochrome P450), metabolites eliminated renally; fecal: negligible.
Primarily renal, with approximately 70% of the dose excreted as unchanged drug in urine and 30% as inactive metabolites. Fecal elimination accounts for <2%.
Category D/X
Category C
Anticonvulsant
Anticonvulsant